Diligence memo · auto-generated · as of July 3, 2026
Cancer Targeting Systems, Inc.
Cancer Targeting Systems, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cancer Targeting Systems, Inc. operates in Biotechnology, based in NEWTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cancer Targeting Systems, Inc. has raised $2.9M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.9M on 2014-09-03.
Most recent recorded round closed around 2014-09-03.
Valuation (modeled)modeled
Provath models Cancer Targeting Systems, Inc. at approximately $129M (range $2.1M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.93× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 11.8 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 33% of Biotechnology peers (4293 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.